Skip to main content
Clinical Trials/NCT04217044
NCT04217044
Recruiting
Not Applicable

Histopathology Images Based Prediction of Molecular Pathology in Glioma Using Deep Learning or Machine Learning

The First Affiliated Hospital of Zhengzhou University1 site in 1 country3,000 target enrollmentJanuary 1, 2017
ConditionsGlioma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Glioma
Sponsor
The First Affiliated Hospital of Zhengzhou University
Enrollment
3000
Locations
1
Primary Endpoint
AUC of prediction performance
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

This registry aims to collect clinical, molecular and radiologic data including detailed clinical parameters, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and images of HE slices in primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine histopathology image based algorithms that are able to predict molecular pathology or subgroups of gliomas.

Detailed Description

Non-invasive and precise prediction for molecular biomarkers such as 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations is challenging. With the development of artificial intelligence, much more potential lies in the histopathology images of HE slices in primary gliomas could be excavated to aid prediction of molecular pathology of gliomas. The creation of a registry for primary glioma with detailed molecular pathology, histopathology image data and with sufficient sample size for deep learning (\>1000) provide considerable opportunities for personalized prediction of molecular pathology with non-invasiveness and precision.

Registry
clinicaltrials.gov
Start Date
January 1, 2017
End Date
June 1, 2027
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
The First Affiliated Hospital of Zhengzhou University
Responsible Party
Principal Investigator
Principal Investigator

Zhenyu Zhang

Principal Investigator

The First Affiliated Hospital of Zhengzhou University

Eligibility Criteria

Inclusion Criteria

  • Patients must have radiologically and histologically confirmed diagnosis of primary glioma
  • Life expectancy of greater than 3 months
  • Must receive tumor resection
  • Signed informed consent

Exclusion Criteria

  • No gliomas
  • No sufficient amount of tumor tissues for detection of molecular pathology
  • Patients who are pregnant or breast feeding
  • Patients who are suffered from severe systematic malfunctions

Outcomes

Primary Outcomes

AUC of prediction performance

Time Frame: up to 10 years

AUC=sensitivity+specificity-1

Study Sites (1)

Loading locations...

Similar Trials